Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$133.08 USD
-0.38 (-0.28%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $133.07 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 381 - 400 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Glimpse of Launch Progress Coming in January as Sarepta Reports 3Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thinking About the US Launch of Exondys 51; Reiterate OUTPERFORM and Raise PT to $72
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Good News Keeps Coming - Interference Case Means Sarepta Should be Able to Launch Unencumbered in the US; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Finally Gets to YES on Eteplirsen; Reiterate OUTPERFORM and Raise PT to $66
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Reports 2Q16 Earnings as We Wait on an Accelerated Approval Decision; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H